Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222652 | 0.94 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL15114678 | 0.83 | HDAC4 (0.35) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL15114393 | 0.82 | HDAC3 (0.34) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL15114677 | 0.79 | HDAC4 (0.36) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL9458910 | 0.78 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL3100734 | 0.76 | HDAC4 (0.36) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3149225 | 0.76 | ALDH1A1 (0.33) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL10581108 | 0.75 | HDAC4 (0.35) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL15114615 | 0.73 | HDAC4 (0.38) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL7769887 | 0.73 | ALDH1A1 (0.37) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| CN-103483151-B | Ebanol preparation method | PUCHENG YONGFANG FRAGRANCE TECHNOLOGY CO LTD | 2015-04-08 | — | — | CN | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| CN-103483151-A | Ebanol preparation method | PUCHENG YONGFANG FRAGRANCE TECHNOLOGY CO LTD | 2014-01-01 | — | — | CN | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-20090010958-A1 | Compositions effective in altering the perception of malodor | PATUS LTD. (IL) | 2009-01-08 | — | — | US | disclosed |
| US-20070065394-A1 | Compositions effective in altering the perception of malodor | PATUS LTD. (IL) | 2007-03-22 | — | — | US | disclosed |
| WO-2005046632-A9 | COMPOSITIONS EFFECTIVE IN ALTERING THE PERCEPTION OF MALODOR | PATUS LTD (IL) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HDAC4 2750/4885HDAC2 2774/4885HDAC8 1456/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | HDAC4 2750/4885HDAC2 2774/4885HDAC8 1456/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HDAC4 2750/4885HDAC2 2774/4885HDAC8 1456/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HDAC4 2750/4885HDAC2 2774/4885HDAC8 1456/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HDAC4 2374/4885HDAC2 2591/4885HDAC8 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.